{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:04:34Z","timestamp":1784729074147,"version":"3.55.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032296","name":"Nuwellis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032296","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Aquadex ultrafiltration system offers a low extracorporeal volume option for the pediatric population. To maintain circuit patency, it relies on conventional anticoagulation, and data on alternative anticoagulation strategies are limited. Epoprostenol, a prostacyclin analog that inhibits platelet aggregation, may provide a safe alternative. The objective of this study was to describe the use of epoprostenol as the sole anticoagulant for Aquadex ultrafiltration therapy in critically ill children and to evaluate its safety, feasibility, and impact on circuit patency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective study of children (&amp;lt;18 years) who received Aquadex therapy with epoprostenol anticoagulation between September 2022 and September 2025 at UPMC Children's Hospital of Pittsburgh. Safety and efficacy were assessed by platelet count, bleeding events, vasoactive-inotropic scores (VIS), and circuit performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-six patients underwent 52 treatments. Median (IQR) age was 35.5 (12.5\u2013114) months. Primary indications were fluid overload (88.5%) and acute kidney injury (11.5%). The median therapy duration was 3 [2\u20139] days, with a filter-to-day ratio of 0.5 (0.3\u20130.5). Platelet counts rose from a median (IQR) of 113 (\u00d710\u2079\/L) prior to therapy to 126 (\u00d710\u2079\/L) at 72\u2005h, with a median of 0 [0\u20131] platelet transfusions per day. The median VIS was 4 [0\u201312] prior to therapy and 0 [0\u20138] at 48\u2005h; vasoactive-inotropic requirements did not increase at any time point. No bleeding events directly attributable to epoprostenol or therapy discontinuations due to hypotension occurred. Circuit patency was maintained, with a median of 0 (0\u20131) interruptions per course due to clotting or clogging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Epoprostenol appears to be a feasible anticoagulant for pediatric Aquadex therapy, with preserved circuit function, no increase in vasoactive-inotropic requirements, and no observed bleeding events. These findings support its further evaluation as an alternative anticoagulant for pediatric Aquadex Therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1858921","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:28:08Z","timestamp":1784726888000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epoprostenol as an alternative anticoagulant for pediatric aquadex therapy: a safe and feasible option"],"prefix":"10.3389","volume":"14","author":[{"given":"Buria","family":"Naeem","sequence":"first","affiliation":[{"name":"Department of Pediatric Critical Care Medicine, Le Bonheur Children's Hospital, University of Tennessee","place":["Memphis, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Harper","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Division of Pediatric Critical Care Medicine, UPMC Children's Hospital of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen","family":"McSteen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Division of Pediatric Critical Care Medicine, UPMC Children's Hospital of Pittsburgh","place":["Pittsburgh, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Y.","family":"Fuhrman","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center","place":["Cincinnati, OH, United States"]},{"name":"Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center","place":["Cincinnati, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.2215\/CJN.03240319","article-title":"Kidney support in children using an ultrafiltration device: a multicenter, retrospective study","volume":"14","author":"Menon","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.4081\/pr.2016.6596","article-title":"Novel use of an ultrafiltration device as an alternative method for fluid removal in critically ill pediatric patients with cardiac disease: a case series","volume":"8","author":"Chakravarti","year":"2016","journal-title":"Pediatr Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00467-015-3259-3","article-title":"Smaller circuits for smaller patients: improving renal support therapy with aquadex","volume":"31","author":"Askenazi","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1051\/ject\/201951163","article-title":"Aquapheresis (AQ) in tandem with extracorporeal membrane oxygenation (ECMO) in pediatric patients","volume":"51","author":"Constantinescu","year":"2019","journal-title":"J Extra Corpor Technol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.clinthera.2021.09.021","article-title":"Real-World anticoagulant use and incidence of venous thromboembolism and Major bleeding in children","volume":"43","author":"Hardin","year":"2021","journal-title":"Clin Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/jth.13913","article-title":"Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues","volume":"16","author":"Newall","year":"2018","journal-title":"J Thromb Haemost"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/PCC.0b013e318292dfa7","article-title":"Anticoagulation for pediatric mechanical circulatory support","volume":"14","author":"Annich","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/0885066621992751","article-title":"A meta-analysis of extracorporeal anticoagulants in pediatric continuous kidney replacement therapy","volume":"37","author":"Raina","year":"2022","journal-title":"J Intensive Care Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/PCC.0000000000003371","article-title":"Epoprostenol (prostacyclin analog) as a sole anticoagulant in continuous renal replacement therapy for critically ill children with liver disease: single-center retrospective study, 2010\u20132019","volume":"25","author":"Deep","year":"2024","journal-title":"Pediatr Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/joneph\/19.5.648","article-title":"Role of prostacyclin (epoprostenol) as anticoagulant in continuous renal replacement therapies: efficacy, security and cost analysis","volume":"19","author":"Gainza","year":"2006","journal-title":"J Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1097\/CCM.0b013e31828a2bbd","article-title":"PELOD-2: an update of the pediatric logistic organ dysfunction score","volume":"41","author":"Leteurtre","year":"2013","journal-title":"Crit Care Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000363204","article-title":"The evolution of pediatric continuous renal replacement therapy","volume":"127","author":"Garzotto","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"B13","first-page":"429","article-title":"Citrate anticoagulation for CRRT: don't Always trust the postfilter iCa results!","volume-title":"Crit Care","author":"Oudemans-van Straaten","year":"2015"},{"key":"B14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1159\/000540302","article-title":"A comparison of the anticoagulation efficacy and safety of epoprostenol to heparin and citrate in children receiving continuous renal replacement therapy","volume":"53","author":"Sondhi","year":"2024","journal-title":"Blood Purif"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1858921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T13:28:09Z","timestamp":1784726889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1858921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":14,"alternative-id":["10.3389\/fped.2026.1858921"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1858921","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1858921"}}